NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026

Journal of the National Comprehensive Cancer Network 2026 Open access

Read full text
Authors: Daniel E. Spratt, Sandy Srinivas, Nabil Adra, Bilawal Ahmed, Yi An, Rhonda Bitting, Brian Chapin, Heather H. Cheng, Steve Y. Cho, Anthony Victor D’Amico, Neil Desai, T. B. Dorff
+29 more James A. Eastham, Thomas A. Farrington, Xin Gao, S Gupta, Joseph E. Ippolito, R. Jeffrey Karnes, Amar U. Kishan, Michael Kuettel, J. Lang, Daniel Lee, Tamara Lotan, Andrew McDonald, Todd M. Morgan, Rodrigo Pessoa, Soroush Rais‐Bahrami, M ROACH, Tyler Robin, Stan Rosenfeld, Kristen R. Scarpato, Tyler Seibert, Ahmad Shabsigh, Russell Szmulewitz, Benjamin A. Teply, Jonathan Tward, Richard Valicenti, David VanderWeele, J.K. Wong, E Kovách, Deborah Freedman-Cass
DOI: 10.6004/jnccn.2026.0023
Cited by: 4
References: 58

Abstract

The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel's discussions on select 2026 updates to the guidelines regarding nonmetastatic disease: the elimination of the very-low-risk group, updates to the Principles of Active Surveillance, and caution in the use of focal therapy in newly diagnosed patients.

Fields of Study & Subjects

Prostate Cancer Diagnosis and Treatment Prostate Cancer Treatment and Research Clinical practice guidelines implementation

Publication details

Journal / source
Journal of the National Comprehensive Cancer Network
Publisher
Harborside Press, LLC
Volume
24
Issue
5
Pages
140–149
Publication date
1 May 2026
Language
EN